cosibelimab-ipdl
AssetAlso called CK-301, TG-1501, Unloxcyt
Blocks PD-L1 to restore antitumor immune responses.
- Stage
- Approved
- Modality
- Antibody
- Target
- CD274
- 15
- Indications
- 6
- Trials
- 2
- Developers
Approved by the FDA on Dec 13, 2024 (BLA761297). FDA
Indications
15Metastatic cutaneous squamous cell carcinoma
Approved, FDA
Locally advanced cutaneous squamous cell carcinoma
Approved, FDA
Metastatic non squamous non small cell lung cancer
Phase 3, Terminated, NCT04786964, clinicaltrials.gov, Nov 12, 2026
12 more
In the full profile
- Target and mechanism2
- Owner and partners2
- Trials6
- Evidence for its targets1
- Competitors12
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.